Unclear when Champix drought will end

Pfizer embarks on total US recall because of carcinogen concerns A total voluntary recall of Pfizer's smoking cessation drug in the US last week because of continued concerns around carcinogen levels appears to have thrown into doubt when the local shortage of Champix (varenicline) might end. In early August the Therapeutic Goods Administration announced that

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous The key to successful digital health
Next World news wrapup: 23 September 2021